Physician profile
Lucy Ledyard
NPI 1528593548
$1,924.14
in general payments reported to CMS, 2019-2025
11 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $282 · 2023: $672 · 2024: $389 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.24 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $781.13 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $327.17 | 2023-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $198.72 | 2022-2025 | |
| Genzyme Corporation | $195.32 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $129.89 | 2022-2025 | Sotyktu |
| Incyte Corporation | $104.45 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.58 | 2024-2025 | Spevigo |
| Amgen INC. | $55.02 | 2022-2024 | Otezla |
| Ucb, INC. | $39.97 | 2022-2024 | Bimzelx |
| Pfizer INC. | $17.84 | 2022 | |
| Organogenesis INC. | $15.05 | 2025 | Affinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Ledyard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.